The American company Regeneron Pharmaceuticals published a press release regarding a clinical study performed by ALYATEC in the environmental exposure chamber.
The positive and promising results of the study were presented for the first time at the virtual 2021 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting.
This phase 2 proof-of-concept trial was designed to evaluate the investigational antibody cocktail REGN1908-1909 in cat-allergic patients with mild asthma.
For any additional information related to the role of ALYATEC in this study, feel free to contact us.
